fluorouracil has been researched along with FMR1-Related Primary Ovarian Insufficiency in 11 studies
Fluorouracil: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.
5-fluorouracil : A nucleobase analogue that is uracil in which the hydrogen at position 5 is replaced by fluorine. It is an antineoplastic agent which acts as an antimetabolite - following conversion to the active deoxynucleotide, it inhibits DNA synthesis (by blocking the conversion of deoxyuridylic acid to thymidylic acid by the cellular enzyme thymidylate synthetase) and so slows tumour growth.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The purpose of this randomized study was to examine if goserelin concomitant to CMF-chemotherapy as adjuvant treatment for premenopausal breast cancer, protects the ovaries from premature failure." | 9.14 | Adjuvant goserelin and ovarian preservation in chemotherapy treated patients with early breast cancer: results from a randomized trial. ( Fornander, T; Johansson, H; Nystedt, M; Sverrisdottir, A, 2009) |
| "Osteoprotegerin (OPG) acts as a decoy receptor for RANK, interrupting osteoclast activation and bone resorption." | 5.42 | Association of osteoprotegerin and bone loss after adjuvant chemotherapy in early-stage breast cancer. ( Lustberg, MB; Oostra, DR; Pan, X; Reinbolt, RE; Shapiro, CL; Wesolowski, R, 2015) |
| "The purpose of this randomized study was to examine if goserelin concomitant to CMF-chemotherapy as adjuvant treatment for premenopausal breast cancer, protects the ovaries from premature failure." | 5.14 | Adjuvant goserelin and ovarian preservation in chemotherapy treated patients with early breast cancer: results from a randomized trial. ( Fornander, T; Johansson, H; Nystedt, M; Sverrisdottir, A, 2009) |
| "In a multi-centre, randomised, controlled study, 1016 premenopausal women received seven series of FEC (F: fluorouracil, E: epirubicin and C: cyclophosphamide) for early stage breast cancer." | 5.14 | The risk of amenorrhoea after adjuvant chemotherapy for early stage breast cancer is related to inter-individual variations in chemotherapy-induced leukocyte nadir in young patients: data from the randomised SBG 2000-1 study. ( Ahlgren, J; Andersen, J; Andersson, M; Bergh, J; Bjerre, K; Blomquist, C; Lidbrink, E; Lindman, H; Mouridsen, H; Rosendahl, M, 2009) |
| "Premenopausal patients with breast cancer are at high risk of premature ovarian failure induced by systemic treatments, but no standard strategies for preventing this adverse effect are yet available." | 2.76 | Effect of the gonadotropin-releasing hormone analogue triptorelin on the occurrence of chemotherapy-induced early menopause in premenopausal women with breast cancer: a randomized trial. ( Bighin, C; Boni, L; Cresti, N; Del Mastro, L; Gamucci, T; Garrone, O; Giordano, M; Giraudi, S; Gori, S; Levaggi, A; Magnolfi, E; Michelotti, A; Olmeo, N; Pronzato, P; Scotto, T; Vecchio, C; Venturini, M, 2011) |
| " Our current study suggests that adjuvant tamoxifen therapy reverses the adverse effects of chemotherapy-induced ovarian failure on total and LDL cholesterol and even lowers their serum levels below the baseline." | 2.71 | Tamoxifen treatment reverses the adverse effects of chemotherapy-induced ovarian failure on serum lipids. ( Blomqvist, C; Elomaa, I; Saarto, T; Taskinen, MR; Vehmanen, L, 2004) |
| "45 premenopausal women with early stage breast cancer were treated with adjuvant chemotherapy." | 2.71 | Short-term intermittent intravenous clodronate in the prevention of bone loss related to chemotherapy-induced ovarian failure. ( Blomqvist, C; Elomaa, I; Risteli, J; Risteli, L; Saarto, T; Vehmanen, L, 2004) |
| "Osteoprotegerin (OPG) acts as a decoy receptor for RANK, interrupting osteoclast activation and bone resorption." | 1.42 | Association of osteoprotegerin and bone loss after adjuvant chemotherapy in early-stage breast cancer. ( Lustberg, MB; Oostra, DR; Pan, X; Reinbolt, RE; Shapiro, CL; Wesolowski, R, 2015) |
| "Tamoxifen use was associated with elevated estradiol levels 1 year post-chemotherapy." | 1.40 | Incidence of chemotherapy-induced ovarian failure in premenopausal women undergoing chemotherapy for breast cancer. ( Ng, CH; Rozita, AM; Taib, NA; Tiong, V; Yip, CH, 2014) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (45.45) | 29.6817 |
| 2010's | 6 (54.55) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Tiong, V | 1 |
| Rozita, AM | 1 |
| Taib, NA | 1 |
| Yip, CH | 1 |
| Ng, CH | 1 |
| Oostra, DR | 1 |
| Lustberg, MB | 1 |
| Reinbolt, RE | 1 |
| Pan, X | 1 |
| Wesolowski, R | 1 |
| Shapiro, CL | 2 |
| Long, JP | 1 |
| Wan, F | 1 |
| Zhang, F | 1 |
| Zhou, J | 1 |
| Don, LF | 1 |
| Sverrisdottir, A | 1 |
| Nystedt, M | 1 |
| Johansson, H | 1 |
| Fornander, T | 1 |
| Rosendahl, M | 1 |
| Ahlgren, J | 1 |
| Andersen, J | 1 |
| Bergh, J | 1 |
| Blomquist, C | 1 |
| Lidbrink, E | 1 |
| Lindman, H | 1 |
| Mouridsen, H | 1 |
| Bjerre, K | 1 |
| Andersson, M | 1 |
| RodrÃguez-Lescure, A | 1 |
| Del Mastro, L | 1 |
| Boni, L | 1 |
| Michelotti, A | 1 |
| Gamucci, T | 1 |
| Olmeo, N | 1 |
| Gori, S | 1 |
| Giordano, M | 1 |
| Garrone, O | 1 |
| Pronzato, P | 1 |
| Bighin, C | 1 |
| Levaggi, A | 1 |
| Giraudi, S | 1 |
| Cresti, N | 1 |
| Magnolfi, E | 1 |
| Scotto, T | 1 |
| Vecchio, C | 1 |
| Venturini, M | 1 |
| Gordon, AM | 1 |
| Hurwitz, S | 1 |
| LeBoff, MS | 1 |
| Vehmanen, L | 2 |
| Saarto, T | 2 |
| Blomqvist, C | 2 |
| Taskinen, MR | 1 |
| Elomaa, I | 2 |
| Risteli, J | 1 |
| Risteli, L | 1 |
| McCune, JS | 1 |
| Games, DM | 1 |
| Espirito, JL | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Prevention of Chemotherapy-induced Menopause by Temporary Ovarian Suppression With Triptorelin Vs. Control in Young Breast Cancer Patients. A Randomized Phase III Multicenter Study [PROMISE][NCT00311636] | Phase 3 | 280 participants (Anticipated) | Interventional | 2003-09-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
5 trials available for fluorouracil and FMR1-Related Primary Ovarian Insufficiency
| Article | Year |
|---|---|
Adjuvant goserelin and ovarian preservation in chemotherapy treated patients with early breast cancer: results from a randomized trial.
Topics: Adult; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neopl | 2009 |
The risk of amenorrhoea after adjuvant chemotherapy for early stage breast cancer is related to inter-individual variations in chemotherapy-induced leukocyte nadir in young patients: data from the randomised SBG 2000-1 study.
Topics: Adult; Age Distribution; Age Factors; Amenorrhea; Antineoplastic Combined Chemotherapy Protocols; Br | 2009 |
Effect of the gonadotropin-releasing hormone analogue triptorelin on the occurrence of chemotherapy-induced early menopause in premenopausal women with breast cancer: a randomized trial.
Topics: Adult; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy | 2011 |
Tamoxifen treatment reverses the adverse effects of chemotherapy-induced ovarian failure on serum lipids.
Topics: Adult; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neopl | 2004 |
Short-term intermittent intravenous clodronate in the prevention of bone loss related to chemotherapy-induced ovarian failure.
Topics: Adult; Antimetabolites; Antineoplastic Combined Chemotherapy Protocols; Bone Resorption; Breast Neop | 2004 |
6 other studies available for fluorouracil and FMR1-Related Primary Ovarian Insufficiency
| Article | Year |
|---|---|
Incidence of chemotherapy-induced ovarian failure in premenopausal women undergoing chemotherapy for breast cancer.
Topics: Adult; Age Factors; Amenorrhea; Antineoplastic Combined Chemotherapy Protocols; Asia; Breast Neoplas | 2014 |
Association of osteoprotegerin and bone loss after adjuvant chemotherapy in early-stage breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyc | 2015 |
DTC chemotherapy regimen is associated with higher incidence of premature ovarian failure in women of reproductive age with breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Docetaxel | 2016 |
Adjuvant chemotherapy in young women with breast cancer.
Topics: Adult; Age Factors; Amenorrhea; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2010 |
Premature ovarian failure and body composition changes with adjuvant chemotherapy for breast cancer.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Body Composition; Brea | 2011 |
Assessment of ovarian failure and osteoporosis in premenopausal breast cancer survivors.
Topics: Absorptiometry, Photon; Administration, Oral; Adult; Age Factors; Antineoplastic Combined Chemothera | 2005 |